NASDAQ:KALV KalVista Pharmaceuticals (KALV) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free kalv Stock Alerts $12.13 -0.04 (-0.33%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$11.96▼$12.4850-Day Range$10.35▼$14.6252-Week Range$7.21▼$16.88Volume199,656 shsAverage Volume697,894 shsMarket Capitalization$511.76 millionP/E RatioN/ADividend YieldN/APrice Target$26.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get KalVista Pharmaceuticals alerts: Email Address KalVista Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside106.1% Upside$25.00 Price TargetShort InterestBearish13.79% of Shares Sold ShortDividend StrengthN/ASustainability-0.79Upright™ Environmental ScoreNews Sentiment0.29Based on 6 Articles This WeekInsider TradingSelling Shares$1.07 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.05) to ($2.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.99 out of 5 starsMedical Sector1063rd out of 5,430 stocksPharmaceutical Preparations Industry409th out of 2,526 stocks 3.5 Analyst's Opinion Consensus RatingKalVista Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKalVista Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.79% of the outstanding shares of KalVista Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverKalVista Pharmaceuticals has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in KalVista Pharmaceuticals has recently increased by 5.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKalVista Pharmaceuticals does not currently pay a dividend.Dividend GrowthKalVista Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKalVista Pharmaceuticals has received a 72.36% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for KalVista Pharmaceuticals is -0.79. Previous Next 2.4 News and Social Media Coverage News SentimentKalVista Pharmaceuticals has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for KalVista Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest1 people have searched for KALV on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, KalVista Pharmaceuticals insiders have sold 112.81% more of their company's stock than they have bought. Specifically, they have bought $503,228.00 in company stock and sold $1,070,918.00 in company stock.Percentage Held by Insiders12.30% of the stock of KalVista Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for KalVista Pharmaceuticals are expected to grow in the coming year, from ($3.05) to ($2.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of KalVista Pharmaceuticals is -3.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KalVista Pharmaceuticals is -3.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKalVista Pharmaceuticals has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Awesomely, LLCAutomatic Income (from home)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. Just click here now to watch my presentation for free. About KalVista Pharmaceuticals Stock (NASDAQ:KALV)KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.Read More KALV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KALV Stock News HeadlinesMay 1, 2024 | finance.yahoo.comKalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal YearApril 22, 2024 | businesswire.comKalVista Pharmaceuticals Appoints William C. Fairey to Board of DirectorsMay 3, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 17, 2024 | fool.comKalVista Pharmaceuticals (NASDAQ: KALV)April 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rallybio (RLYB), Phathom Pharmaceuticals (PHAT) and Amylyx Pharmaceuticals Inc (AMLX)April 3, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)April 3, 2024 | businesswire.comKalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare ConferenceApril 2, 2024 | businesswire.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 3, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).March 18, 2024 | finance.yahoo.comKalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference AmericasMarch 12, 2024 | markets.businessinsider.comBuy Rating on KalVista Pharmaceuticals Backed by Sebetralstat’s Breakthrough in HAE TreatmentMarch 12, 2024 | finance.yahoo.comKalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for SebetralstatMarch 11, 2024 | markets.businessinsider.comBuy Rating Reinforced by Strategic CEO Appointment and Promising Drug Development at KalVista PharmaceuticalsMarch 11, 2024 | businesswire.comKalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational UpdateMarch 8, 2024 | finanznachrichten.deKalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference AmericasMarch 8, 2024 | businesswire.comKalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference AmericasMarch 7, 2024 | marketwatch.comKalVista Pharmaceuticals Stock Falls After CEO ResignsMarch 7, 2024 | markets.businessinsider.comKalVista Stock Drops After Announcement Of Resignation Of CEO Andrew CrockettMarch 7, 2024 | marketwatch.comKalVista Pharmaceuticals Names Benjamin Palleiko Chief Executive, DirectorMarch 7, 2024 | businesswire.comKalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive OfficerMarch 6, 2024 | businesswire.comKalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma ConferenceMarch 4, 2024 | businesswire.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 28, 2024 | investing.comKalVista reports high efficacy for HAE drug in phase 3 trialFebruary 27, 2024 | finance.yahoo.comKalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual MeetingFebruary 27, 2024 | businesswire.comKalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual MeetingFebruary 26, 2024 | businesswire.comKalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual MeetingFebruary 25, 2024 | msn.comKalVista Pharmaceuticals (KALV) Price Target Increased by 51.92% to 32.23See More Headlines Receive KALV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today5/03/2024Next Earnings (Estimated)7/05/2024Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KALV CUSIPN/A CIK1348911 Webwww.kalvista.com Phone857-999-0075Fax866-553-3269Employees118Year FoundedN/APrice Target and Rating Average Stock Price Target$26.33 High Stock Price Target$35.00 Low Stock Price Target$20.00 Potential Upside/Downside+119.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,910,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-86.06% Return on Assets-72.65% Debt Debt-to-Equity RatioN/A Current Ratio5.44 Quick Ratio5.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.71 per share Price / Book2.55Miscellaneous Outstanding Shares42,190,000Free Float36,999,000Market Cap$507.12 million OptionableOptionable Beta0.92 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Benjamin L. Palleiko (Age 58)CEO & Director Comp: $707.1kDr. Christopher M. Yea Ph.D. (Age 60)Chief Development Officer Comp: $640.23kDr. Edward P. Feener Ph.D. (Age 64)Chief Scientific Officer Comp: $506kMr. Ryan BakerHead of Investor RelationsMr. Brian Krex J.D. (Age 56)General Counsel Jarrod AldomVice President of Corporate CommunicationsMs. Rachel M. MortenSenior Vice President of Regulatory Affairs & QADr. Michael D. Smith Pharm.D. (Age 44)Senior Vice President of Development Dr. Paul K. Audhya M.B.A. (Age 51)M.D., Chief Medical Officer Ms. Nicole Sweeny (Age 48)Chief Commercial Officer More ExecutivesKey CompetitorsArbutus BiopharmaNASDAQ:ABUSAltimmuneNASDAQ:ALTShattuck LabsNASDAQ:STTKKorro BioNASDAQ:KRROVerve TherapeuticsNASDAQ:VERVView All CompetitorsInsiders & InstitutionsBNP Paribas Financial MarketsBought 8,750 shares on 5/1/2024Ownership: 0.043%Principal Financial Group Inc.Sold 1,295 shares on 4/29/2024Ownership: 0.024%China Universal Asset Management Co. Ltd.Bought 4,043 shares on 4/29/2024Ownership: 0.019%Rosalind Advisors Inc.Sold 12,015 shares on 4/25/2024Ownership: 0.683%Thomas Andrew CrockettSold 24,888 sharesTotal: $351,169.68 ($14.11/share)View All Insider TransactionsView All Institutional Transactions KALV Stock Analysis - Frequently Asked Questions Should I buy or sell KalVista Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KalVista Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KALV shares. View KALV analyst ratings or view top-rated stocks. What is KalVista Pharmaceuticals' stock price target for 2024? 3 analysts have issued 12 month target prices for KalVista Pharmaceuticals' stock. Their KALV share price targets range from $20.00 to $35.00. On average, they expect the company's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 106.1% from the stock's current price. View analysts price targets for KALV or view top-rated stocks among Wall Street analysts. How have KALV shares performed in 2024? KalVista Pharmaceuticals' stock was trading at $12.25 at the beginning of the year. Since then, KALV shares have decreased by 1.0% and is now trading at $12.13. View the best growth stocks for 2024 here. Are investors shorting KalVista Pharmaceuticals? KalVista Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 5,520,000 shares, an increase of 12.2% from the March 15th total of 4,920,000 shares. Based on an average daily volume of 809,700 shares, the days-to-cover ratio is currently 6.8 days. View KalVista Pharmaceuticals' Short Interest. When is KalVista Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, July 5th 2024. View our KALV earnings forecast. How were KalVista Pharmaceuticals' earnings last quarter? KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) announced its earnings results on Monday, March, 11th. The specialty pharmaceutical company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.75) by $0.09. What other stocks do shareholders of KalVista Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Pfizer (PFE). Who are KalVista Pharmaceuticals' major shareholders? KalVista Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Rosalind Advisors Inc. (0.68%), BNP Paribas Financial Markets (0.04%), Principal Financial Group Inc. (0.02%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Albert Cha, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Miami Jewish Federatio Greater, Michael David Smith, Paul K Audhya, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View institutional ownership trends. How do I buy shares of KalVista Pharmaceuticals? Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KALV) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap Profits4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
